AB0905 Long-term (5-YEAR) efficacy and safety of apremilast monotherapy in dmard-naÏve subjects with active psoriatic arthritis
A. Wells(Center for Rheumatology), Jacob Aelion(Middle Tennessee Research Institute), Nikolay Delev(Bristol-Myers Squibb (Sweden)), A. Kivitz(Altoona Center for Clinical Research), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Maria Paris(Amgen (United States)), B. Guérette, Lichen Teng(Harbin Medical University), Paul Bird(UNSW Sydney)
Cited by 0
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis
|Annals of the Rheumatic Diseases|2013|668